KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accounts Payables (2017 - 2025)

Moderna (MRNA) has disclosed Accounts Payables for 9 consecutive years, with $317.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 21.73% to $317.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $317.0 million, a 21.73% decrease, with the full-year FY2025 number at $317.0 million, down 21.73% from a year prior.
  • Accounts Payables was $317.0 million for Q4 2025 at Moderna, up from $267.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $520.0 million in Q4 2023 to a low of $8.0 million in Q1 2021.
  • A 5-year average of $280.4 million and a median of $290.5 million in 2021 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: soared 2387.5% in 2022, then crashed 52.96% in 2024.
  • Moderna's Accounts Payables stood at $302.0 million in 2021, then soared by 61.26% to $487.0 million in 2022, then increased by 6.78% to $520.0 million in 2023, then decreased by 22.12% to $405.0 million in 2024, then decreased by 21.73% to $317.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Accounts Payables are $317.0 million (Q4 2025), $267.0 million (Q3 2025), and $175.0 million (Q2 2025).